...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: AGM - High Level Summary
7
Jan 07, 2016 03:54PM
2
Jan 07, 2016 03:58PM
4
Jan 07, 2016 06:25PM
4
Jan 07, 2016 06:59PM
2
Jan 07, 2016 07:35PM
7
Jan 07, 2016 11:57PM
3
Jan 08, 2016 12:06AM
4
Jan 08, 2016 07:18AM
2
Jan 08, 2016 01:40PM
2
Jan 08, 2016 03:07PM

Hi fouremm.

Thanks for this. I'm not too good at understanding the share structure. So let's say, for example, I own 50,000 Zenith shares pre-reorg. So after the reorg I own 50,000 shares of ZCC. So let's say that Zenith epigenetics goes public with ZEN3694 then I will own 50,000 share of this new public company and I will still own 50,000 in ZCC?????

Does that sound right?

Thanks

Toinv

3
Jan 12, 2016 05:38PM
1
Jan 12, 2016 06:19PM

Jan 12, 2016 06:48PM
5
Jan 12, 2016 08:25PM
1
Jan 12, 2016 08:50PM
5
Jan 12, 2016 10:14PM
3
Jan 12, 2016 11:04PM
4
Jan 13, 2016 08:58AM
5
Jan 13, 2016 01:37PM
1
Jan 13, 2016 02:01PM
Share
New Message
Please login to post a reply